- Home
- CVKD vs CODX Comparison
CVKD vs CODX Comparison
Compare CVKD & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | CODX |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 15.6M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CVKD | CODX |
|---|---|---|
| Price | $9.94 | $0.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $32.00 | $2.25 |
| AVG Volume (30 Days) | 28.8K | ★ 1.7M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.12 | $0.23 |
| 52 Week High | $22.90 | $1.55 |
Technical Indicators
Market Signals| Indicator | CVKD | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 48.75 |
| Support Level | $8.12 | $0.34 |
| Resistance Level | $11.58 | $0.41 |
| Average True Range (ATR) | 0.88 | 0.04 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 46.06 | 44.42 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.